Background: The treatment of metachronous Krukenberg tumor (mKT) from gastric cancer remains unexplored. We performed a literature review to evaluate whether or not surgical treatment improves survival. Methods: A systematic review according to PRISMA guidelines was performed. Studies reporting on patients who underwent surgical treatment for mKT from gastric cancer were selected. Metachronous disease was divided as follows: confined to the ovaries, confined to the pelvis, or beyond the pelvis. Outcomes evaluated included overall survival (OS), progression-free survival (PFS), resection rate (R0), and factors predicting survival. Results: 13 retrospective reports fulfilled the selection criteria (512 patients). Most of the patients presented at a premenopausal age. The median presentation interval from gastrectomy ranged from 16 to 21.4 months. Median OS ranged between 9 and 36 months. 1-year OS ranged between 52.5 and 59%, and 3-years OS between 9.8 and 36.5%. Resection margin, peritoneal seeding, and chemotherapy regimen and cycles influenced survival. Conclusion: Surgical treatment and adjuvant chemotherapy in patients with mKT from gastric cancer seems to be associated with improved survival and is justified especially in young patients. Disease location and R0 resection should be considered when selecting patients.

Journal Section:
Systematic Review
Keywords:
Krukenberg tumor, Gastric cancer, Overall survival
1.
Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
[PubMed]
https://doi.org/10.3322/caac.21208
2.
Holtz F, Hart WR: Krukenberg tumors of the ovary: a clinicopathologic analysis of 27 cases. Cancer 1982;50:2438-2447.
[PubMed]
https://doi.org/10.1002/1097-0142(19821201)50:11<2438::AID-CNCR2820501132>3.0.CO;2-X
3.
Sugarbaker PH, Averbach AM: Krukenberg syndrome as a natural manifestation of tumor cell entrapment. Cancer Treat Res 1996;82:163-191.
[PubMed]
4.
Woodruff JD, Novak ER: The Krukenberg tumor: study of 48 cases from the ovarian tumor registry. Obstet Gynecol 1960;15:351-360.
[PubMed]
5.
Duarte I, Llanos O: Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. Hum Pathol 1981;12:237-242.
[PubMed]
https://doi.org/10.1016/S0046-8177(81)80124-4
6.
Yoo CH, Noh SH, Shin DW, Choi SH, Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-242.
[PubMed]
https://doi.org/10.1046/j.1365-2168.2000.01360.x
7.
Jun SY, Park JK: Metachronous ovarian metastases following resection of the primary gastric cancer. J Gastric Cancer 2011;11:31-37.
[PubMed]
https://doi.org/10.5230/jgc.2011.11.1.31
8.
Rosa F, Marrelli D, Morgagni P, Cipollari C, Vittimberga G, Framarini M, Cozzaglio L, Pedrazzani C, Berardi S, Baiocchi GL, Roviello F, Portolani N, de Manzoni G, Costamagna G, Doglietto GB, Pacelli F: Krukenberg tumors of gastric origin: the rationale of surgical resection and perioperative treatments in a multicenter western experience. World J Surg 2016;40:921-928.
[PubMed]
https://doi.org/10.1007/s00268-015-3326-8
9.
Demopoulos RI, Touger L, Dubin N: Secondary ovarian carcinoma: a clinical and pathological evaluation. Int J Gynecol Pathol 1987;6:166-175.
[PubMed]
10.
McGill FM, Ritter DB, Rickard CS, Kaleya RN, Wadler S, Greston WM, O'Hanlan KA: Krukenberg tumors: can management be improved? Gynecol Obstet Invest 1999;48:61-65.
[PubMed]
https://doi.org/10.1159/000010136
11.
Petru E, Pickel H, Heydarfadai M, Lahousen M, Haas J, Schaider H, Tamussino K: Nongenital cancers metastatic to the ovary. Gynecol Oncol 1992;44:83-86.
[PubMed]
https://doi.org/10.1016/0090-8258(92)90017-D
12.
Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH: Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecol Oncol 2004;94:477-482.
[PubMed]
https://doi.org/10.1016/j.ygyno.2004.05.007
13.
Matsushita H, Watanabe K, Wakatsuki A: Metastatic gastric cancer to the female genital tract. Mol Clin Oncol 2016;5:495-499.
[PubMed]
https://doi.org/10.3892/mco.2016.1035
14.
Song KY, Park SM, Kim SN, Park CH: The role of surgery in the treatment of recurrent gastric cancer. Am J Surg 2008;196:19-22.
[PubMed]
https://doi.org/10.1016/j.amjsurg.2007.05.056
15.
Downs SH, Black N: The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-384.
[PubMed]
https://doi.org/10.1136/jech.52.6.377
16.
Lerwill MF, Young RH: Ovarian metastases of intestinal-type gastric carcinoma: a clinicopathologic study of 4 cases with contrasting features to those of the Krukenberg tumor. Am J Surg Pathol 2006;30:1382-1388.
[PubMed]
https://doi.org/10.1097/01.pas.0000213256.75316.4a
17.
Mrad K, Morice P, Fabre A, Pautier P, Lhomme C, Duvillard P, Sabourin JC: Krukenberg tumor: a clinico-pathological study of 15 cases. Ann Pathol 2000;20:202-206.
[PubMed]
18.
Brieau B, Auzolle C, Pozet A, Tougeron D, Bouche O, Soibinet P, Coriat R, Prieux C, Lecomte T, Goujon G, Marthey L, Rougier P, Bonnetain F, Ducreux M, Taieb J, Zaanan A: Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: a retrospective AGEO multicentre study. Dig Liver Dis 2016;48:441-445.
[PubMed]
https://doi.org/10.1016/j.dld.2015.12.012
19.
Jiang R, Tang J, Cheng X, Zang RY: Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol 2009;35:92-97.
[PubMed]
https://doi.org/10.1016/j.ejso.2008.05.006
20.
Lee M, Paek J, Lee SH, Yim GW, Kim SW, Kim S, Kim JH, Kim YT, Nam EJ: Feasibility and surgical outcomes of laparoscopic metastasectomy in the treatment of ovarian metastases from gastric cancer. Int J Gynecol Cancer 2011;21:1306-1311.
[PubMed]
https://doi.org/10.1097/IGC.0b013e31822620e3
21.
Lu LC, Shao YY, Hsu CH, Hsu C, Cheng WF, Lin YL, Cheng AL, Yeh KH: Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer. Anticancer Res 2012;32:3397-3401.
[PubMed]
22.
Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Endou Y, Sasaki T: Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am 2003;12:635-648.
[PubMed]
https://doi.org/10.1016/S1055-3207(03)00035-8
23.
Kim HK, Heo DS, Bang YJ, Kim NK: Prognostic factors of Krukenberg's tumor. Gynecol Oncol 2001;82:105-109.
[PubMed]
https://doi.org/10.1006/gyno.2001.6210
24.
Ayhan A, Guvenal T, Salman MC, Ozyuncu O, Sakinci M, Basaran M: The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries. Gynecol Oncol 2005;98:235-241.
[PubMed]
https://doi.org/10.1016/j.ygyno.2005.05.028
25.
Cho JH, Lim JY, Choi AR, Choi SM, Kim JW, Choi SH, Cho JY: Comparison of surgery plus chemotherapy and palliative chemotherapy alone for advanced gastric cancer with Krukenberg tumor. Cancer Res Treat 2015;47:697-705.
[PubMed]
https://doi.org/10.4143/crt.2013.175
26.
Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH: Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer. J Surg Oncol 2004;87:39-45.
[PubMed]
https://doi.org/10.1002/jso.20072
27.
Feng Q, Pei W, Zheng ZX, Bi JJ, Yuan XH: Clinicopathologic characteristics and prognostic factors of 63 gastric cancer patients with metachronous ovarian metastasis. Cancer Biol Med 2013;10:86-91.
[PubMed]
https://doi.org/10.7497/j.issn.2095-3941.2013.02.004
28.
Jeung YJ, Ok HJ, Kim WG, Kim SH, Lee TH: Krukenberg tumors of gastric origin versus colorectal origin. Obstet Gynecol Sci 2015;58:32-39.
[PubMed]
https://doi.org/10.5468/ogs.2015.58.1.32
29.
Kikkawa F, Ino K, Nomura S, Ishikawa H, Kuzuya K, Yamamuro O, Kobayashi I, Kawai M, Mizutani S: Prognostic factors of secondary ovarian carcinoma. Oncology 2002;63:124-129.
[PubMed]
https://doi.org/10.1159/000063805
30.
Kobayashi O, Sugiyama Y, Cho H, Tsuburaya A, Sairenji M, Motohashi H, Yoshikawa T: Clinical and pathological study of gastric cancer with ovarian metastasis. Int J Clin Oncol 2003;8:67-71.
[PubMed]
https://doi.org/10.1007/s101470300012
31.
Lee SJ, Bae JH, Lee AW, Tong SY, Park YG, Park JS: Clinical characteristics of metastatic tumors to the ovaries. J Korean Med Sci 2009;24:114-119.
[PubMed]
https://doi.org/10.3346/jkms.2009.24.1.114
32.
Peng W, Hua RX, Jiang R, Ren C, Jia YN, Li J, Guo WJ: Surgical treatment for patients with Krukenberg tumor of stomach origin: clinical outcome and prognostic factors analysis. PLoS One 2013;8:e68227.
[PubMed]
https://doi.org/10.1371/journal.pone.0068227
33.
Wang J, Shi YK, Wu LY, Wang JW, Yang S, Yang JL, Zhang HZ, Liu SM: Prognostic factors for ovarian metastases from primary gastric cancer. Int J Gynecol Cancer 2008;18:825-832.
[PubMed]
https://doi.org/10.1111/j.1525-1438.2007.01078.x
34.
Wu XJ, Yuan P, Li ZY, Bu ZD, Zhang LH, Wu AW, Zong XL, Li SX, Shan F, Ji X, Ren H, Ji JF: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour Biol 2013;34:463-469.
[PubMed]
https://doi.org/10.1007/s13277-012-0571-4
35.
Yook JH, Oh ST, Kim BS: Clinical prognostic factors for ovarian metastasis in women with gastric cancer. Hepatogastroenterology 2007;54:955-959.
[PubMed]
36.
Yu P, Huang L, Cheng G, Yang L, Dai G, Ying J, Du Y: Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget 2017;8:82558-82570.
[PubMed]
https://doi.org/10.18632/oncotarget.19759
37.
Agnes A, Biondi A, Ricci R, Gallotta V, D'Ugo D, Persiani R: Krukenberg tumors: seed, route and soil. Surg Oncol 2017;26:438-445.
[PubMed]
https://doi.org/10.1016/j.suronc.2017.09.001
© 2018 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.